Agrawal Gautam, Agarwal Bhawna, Shirsat Pallavi, Sonavane Kunal
Nephrology, Independence Health System, Greensburg, USA.
Internal Medicine, University of Pittsburgh Medical Center, McKeesport Hospital, McKeesport, USA.
Cureus. 2025 Apr 4;17(4):e81717. doi: 10.7759/cureus.81717. eCollection 2025 Apr.
Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disorder characterized by the progressive development of renal cysts, ultimately leading to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Patients are typically diagnosed in their 20s or 30s, and the majority have a parent with a known history of the condition. The most common gene mutations associated with ADPKD are and , although other mutations have also been identified. Kidney enlargement rates can vary and serve as a marker for ADPKD progression and the eventual decline in kidney function. The Mayo Imaging Classification (MIC) tool assesses the risk of progression by incorporating height-adjusted total kidney volume (htTKV) and the patient's age. Tolvaptan is recommended for patients at high risk of progression, although it has not been studied in individuals over the age of 65. This case report focuses on the diagnosis and management of ADPKD in a 66-year-old male with no known family history of the condition. Genetic testing revealed an gene mutation, typically associated with a less severe phenotype. However, the patient was classified as 1C according to the MIC, indicating a high risk of disease progression. This case underscores the challenges of managing severe disease in older patients, given the limited research available for this age group.
常染色体显性多囊肾病(ADPKD)是一种常见的遗传性疾病,其特征是肾囊肿逐渐发展,最终导致慢性肾脏病(CKD)和终末期肾病(ESRD)。患者通常在二三十岁时被诊断出来,大多数患者的父母有该疾病的已知病史。与ADPKD相关的最常见基因突变是 和 ,不过也发现了其他突变。肾脏增大速率会有所不同,可作为ADPKD进展及最终肾功能下降的一个标志。梅奥影像分类(MIC)工具通过纳入身高校正后的总肾体积(htTKV)和患者年龄来评估疾病进展风险。托伐普坦被推荐用于进展风险高的患者,不过尚未在65岁以上人群中进行研究。本病例报告聚焦于一名66岁、无该疾病家族史男性患者的ADPKD诊断与管理。基因检测发现一个 基因突变,该突变通常与不太严重的表型相关。然而,根据MIC该患者被归类为1C,表明疾病进展风险高。鉴于针对该年龄组的研究有限,本病例凸显了老年患者严重疾病管理方面的挑战。